NewsBenzingaStifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Benzinga 2026.11.10 14:20 (GMT+0) Open on Benzinga Other news Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Z Squared Secures 5-Yr Option To Acquire Nearly 90 Acres Near Arkansas Campus, Terms Undisclosed Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday Truist Securities Downgrades Lucky Strike to Hold, Lowers Price Target to $4.35